Pharmacological Properties of 3-Amino-5,6,7,8-tetrahydro-2-{4-[4-(quinolin-2-yl)piperazin-1-yl]butyl}quinazolin-4(3H)-one (TZB-30878), a Novel Therapeutic Agent for Diarrhea-Predominant Irritable Bowel Syndrome (IBS) and Its Effects on an Experimental IBS Model

2007 ◽  
Vol 322 (3) ◽  
pp. 1315-1323 ◽  
Author(s):  
Satoru Tamaoki ◽  
Yukinao Yamauchi ◽  
Youichi Nakano ◽  
Sayuri Sakano ◽  
Akira Asagarasu ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Therapeutic Agent ◽  
Pharmacological Properties ◽  
Irritable Bowel ◽  
Novel Therapeutic

scholarly journals Evaluation of the Pharmacological Profile of Ramosetron, a Novel Therapeutic Agent for Irritable Bowel Syndrome

2007 ◽  
Vol 104 (3) ◽  
pp. 263-273 ◽  
Author(s):  
Takuya Hirata ◽  
Yoshihiro Keto ◽  
Toshiyuki Funatsu ◽  
Shinobu Akuzawa ◽  
Masao Sasamata
Keyword(s):  
Irritable Bowel Syndrome ◽  
Therapeutic Agent ◽  
Pharmacological Profile ◽  
Irritable Bowel ◽  
Novel Therapeutic

scholarly journals Pharmacological and clinical profile of ramosetron hydrochloride (Irribow®), a novel therapeutic agent for irritable bowel syndrome with diarrhea

2009 ◽  
Vol 133 (5) ◽  
pp. 281-291
Author(s):  
Takuya Hirata ◽  
Toshiyuki Funatsu ◽  
Yoshihiro Keto ◽  
Shinobu Akuzawa ◽  
Hiraku Akiho ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Therapeutic Agent ◽  
Clinical Profile ◽  
Irritable Bowel ◽  
Novel Therapeutic

scholarly journals A sustained hypothalamic–pituitary–adrenal axis response to acute psychosocial stress in irritable bowel syndrome

2014 ◽  
Vol 44 (14) ◽  
pp. 3123-3134 ◽  
Author(s):  
P. J. Kennedy ◽  
J. F. Cryan ◽  
E. M. M. Quigley ◽  
T. G. Dinan ◽  
G. Clarke
Keyword(s):  
Irritable Bowel Syndrome ◽  
Hpa Axis ◽  
Psychosocial Stress ◽  
Trier Social Stress Test ◽  
Hypothalamic Pituitary Adrenal ◽  
Gi Symptoms ◽  
Irritable Bowel ◽  
Acute Psychosocial Stress ◽  
Novel Therapeutic ◽  
The Way

BackgroundDespite stress being considered a key factor in the pathophysiology of the functional gastrointestinal (GI) disorder irritable bowel syndrome (IBS), there is a paucity of information regarding the ability of IBS patients to respond to acute experimental stress. Insights into the stress response in IBS could open the way to novel therapeutic interventions. To this end, we assessed the response of a range of physiological and psychological parameters to the Trier Social Stress Test (TSST) in IBS.MethodThirteen female patients with IBS and 15 healthy female age-matched control participants underwent a single exposure to the TSST. Salivary cortisol, salivary C-reactive protein (CRP), skin conductance level (SCL), GI symptoms, mood and self-reported stress were measured pre- and post-exposure to the TSST.ResultsThe hypothalamic–pituitary–adrenal (HPA) axis response to the TSST was sustained in IBS, as shown by a greater total cortisol output throughout (p = 0.035) and higher cortisol levels measured by an area under the curve with respect to ground (AUCG) analysis (p = 0.044). In IBS patients, GI symptoms increased significantly during the recovery period following exposure to the TSST (p = 0.045). Salivary CRP and SCL activity showed significant changes in relation to stress but with no differential effect between experimental groups.ConclusionsPatients with IBS exhibit sustained HPA axis activity, and an increase in problematic GI symptoms in response to acute experimental psychosocial stress. These data pave the way for future interventional studies aimed at identifying novel therapeutic approaches to modulate the HPA axis and GI symptom response to acute psychosocial stress in IBS.

Novel therapeutic approaches in the treatment of irritable bowel syndrome

2007 ◽  
Vol 148 (20) ◽  
pp. 923-928 ◽  
Author(s):  
István Pregun ◽  
László Herszényi ◽  
Márk Juhász ◽  
Pál Miheller ◽  
Zsolt Tulassay
Keyword(s):  
Irritable Bowel Syndrome ◽  
Therapeutic Approaches ◽  
Irritable Bowel ◽  
Novel Therapeutic

Az irritábilis bél szindróma (IBS) kezelése a változatos tünetek, a társuló neuropszichiátriai kórképek miatt nem könnyű feladat. Bár számos, különböző támadáspontú szert alkalmazunk a betegség kezelésére, a mai napig kevés olyan gyógyszer van, amelynek hatékonyságáról, biztonságosságáról és tolerabilitásáról egyértelmű bizonyítékok állnak rendelkezésre. Az IBS multikauzális jellegéből adódóan a visceralis hiperszenzitivitással, a motilitással, az agy-bél tengely szabályozási zavaraival kapcsolatos kutatások eredményei, a folyamatokban központi szerepet játszó neurotranszmitterek, ezek receptorainak megismerése teremtette meg az új kezelési lehetőségek alapját. Bár napjainkban néhány gyógyszert (alosetron, tegaserod) már törzskönyveztek egyes országokban IBS-ben, az új készítményekkel kapcsolatban még több, nagy betegszámú vizsgálatra van szükség.

scholarly journals Agomelatine, a novel therapeutic option for the management of irritable bowel syndrome

2018 ◽  
Vol 43 (5) ◽  
pp. 752-756 ◽  
Author(s):  
Qin Xiang Ng ◽  
Alex Yu Sen Soh ◽  
Donovan Yutong Lim ◽  
Wee‐Song Yeo
Keyword(s):  
Irritable Bowel Syndrome ◽  
Therapeutic Option ◽  
Irritable Bowel ◽  
Novel Therapeutic

Su1988 Novel Therapeutic Approaches for Treatment of Irritable Bowel Syndrome Using the Multi-Herbal Drug STW 5

2012 ◽  
Vol 142 (5) ◽  
pp. S-554
Author(s):  
Karen Nieber ◽  
Ulrike Voss ◽  
Stefanie Hoser ◽  
Sebastian Michael ◽  
Heba Abdel-Aziz ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Herbal Drug ◽  
Therapeutic Approaches ◽  
Irritable Bowel ◽  
Novel Therapeutic

scholarly journals Pharmacological properties of NIP-530, a novel therapeutic agent for atopic dermatitis.

1999 ◽  
Vol 79 ◽  
pp. 287
Author(s):  
Akiko Yamamoto ◽  
Takehisa Iwama ◽  
Yoichiro Fujita ◽  
Yasuhito Suzuki ◽  
Kanako Takahashi ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Therapeutic Agent ◽  
Pharmacological Properties ◽  
Novel Therapeutic
Sign in / Sign up

Export Citation Format

Share Document